We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Osimertinib

News List

AZ’ Tagrisso offers sustained benefit in lung cancer pharmatimes
July 17, 2018
AstraZeneca says that the “unprecedented progression-free survival benefit” of Tagrisso when used as a first line treatment for lung cancer is sustained through subsequent lines of therapy.
AZ’ lung cancer drug Tagrisso backed for first-line use pharmatimes
July 12, 2018
European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting.
EU approves first-line use of AZ’ Tagrisso in lung cancer pharmatimes
July 10, 2018
AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.

Previous page 1 2 Next page